NEW YORK, Oct. 25, 2012 /PRNewswire/ -- Griffin Securities announced today that Dr. Keith Markey, the Scientific Director of Griffin's research division, recently interviewed Alan Shortall, CEO of Unilife Corporation ("Unilife") (NASDAQ: UNIS; ASX: UNS) about the company's continued progress in the commercialization of its portfolio of proprietary injectable drug delivery systems as well as a Q&A covering many investor questions that have arose over the past few weeks.
The video interview series will be made available in two parts:
- Part One – Update on the Unilife Business and Financial Discussion
- Part Two – Unilife's Device Platforms and New Commercial Opportunities
Part Two of the video interview and associated transcript will be made available to the public at 9.30 a.m. U.S. Eastern Time, Friday, October 26, 2012. Links to this Part Two of the interview will be provided at this time."I believe this two part video series offers an in-depth overview of the questions that Unilife investors have been asking recently as it pertains to the business and the company's stock. Alan opens up about why investing in R&D is so important for Unilife as a business and the short-term impacts as well as the long-term opportunities for Unilife as it pertains to the company's relationships with its pharmaceutical company customers," stated Dr. Markey. For Griffin Securities' reports on Unilife Corporation, including full disclosure statements, please contact Dr. Keith Markey at 212-514-7914 or via email, email@example.com. About Unilife Corporation Unilife Corporation (NASDAQ:UNIS / ASX: UNS) is a U.S. based developer and commercial supplier of injectable drug delivery systems. Unilife collaborates with pharmaceutical and biotechnology companies seeking innovative, differentiated devices that can enable or enhance the delivery of injectable drugs and vaccines supplied in either a liquid stable or lyophilized form. The Unifill syringe, the world's first and only prefilled syringe with fully integrated safety features, sits at the leading edge of this diversified portfolio. In addition to prefilled and hypodermic safety syringes with automatic, user-controlled needle retraction, Unilife has other proprietary technology platforms including drug reconstitution delivery systems, auto-injectors, bolus injectors, infusion pumps and targeted delivery systems. Unilife's global headquarters and state-of-the-art manufacturing facilities are located in York, PA. For more information on Unilife, please visit www.unilife.com. About Griffin Securities, Inc. ("Griffin Securities") Griffin Securities, a FINRA (formerly known as the NASD) member firm with its principal office in New York, New York, USA is an investment banking firm providing corporate finance, merger and acquisitions, brokerage, and investment opportunities for institutional, corporate, and private clients. The analyst(s) are employed by Griffin Securities. Our research professionals provide important input into our investment banking and other business selection processes. Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. Griffin Securities may from time to time perform corporate finance or other services for some companies described herein and may occasionally possess material, nonpublic information regarding such companies. This information is not used in preparation of the opinions and estimates herein. While the information contained in this report and the opinions contained herein are based on sources believed to be reliable, Griffin Securities has not independently verified the facts, assumptions and estimates contained in this report. Accordingly, no representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information and opinions contained in this report.